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Abstract
Introduction BRCA1 or BRCA2 germline mutations increase
the risk of developing breast cancer. Tumour cells from germline
mutation carriers have frequently lost the wild-type allele. This is
predicted to result in genomic instability where cell survival
depends upon dysfunctional checkpoint mechanisms.
Tumorigenic potential could then be acquired through further
genomic alterations. Surprisingly, somatic BRCA mutations are
not found in sporadic breast tumours. BRCA1 methylation has
been shown to occur in sporadic breast tumours and to be
associated with reduced gene expression. We examined the
frequency of BRCA1  methylation in 143 primary sporadic
breast tumours along with BRCA1 copy number alterations and
tumour phenotype.
Methods Primary sporadic breast tumours were analysed for
BRCA1α  promoter methylation by methylation specific PCR
and for allelic imbalance (AI) at BRCA1 and BRCA2 loci by
microsatellite analysis and TP53 (also known as p53) mutations
by constant denaturing gel electrophoresis. The BRCA1
methylated tumours were analysed for BRCA1 copy alterations
by fluorescence in situ hybridisation and BRCA1 expression by
immunostaining.
Results  BRCA1  methylation was found in 13/143 (9.1%)
sporadic breast tumours. The BRCA1 methylated tumours were
significantly associated with estrogen receptor (ER) negativity
(P = 0.0475) and displayed a trend for BRCA1 AI (P = 0.0731)
as well as young-age at diagnosis (≤ 55; P = 0.0898). BRCA1
methylation was not associated with BRCA2 AI (P = 0.5420),
although a significant association was found between BRCA1
AI and BRCA2 AI (P < 0.0001).
Absent/markedly reduced BRCA1 expression was observed in
9/13 BRCA1 methylated tumours, most of which had BRCA1
deletion. An elevated TP53  mutation frequency was found
among  BRCA1  methylated tumours (38.5%) compared with
non-methylated tumours (17.2%). The BRCA1  methylated
tumours were mainly of tumour grade 3 (7/13) and infiltrating
ductal type (12/13). Only one methylated tumour was of grade 1.
Conclusion BRCA1 methylation is frequent in primary sporadic
breast tumours. We found an indication for BRCA1 methylation
to be associated with AI at the BRCA1 locus. Almost all BRCA1
methylated tumours with absent/markedly reduced BRCA1
expression (8/9) displayed BRCA1 deletion. Thus, epigenetic
silencing and deletion of the BRCA1  gene might serve as
Knudson's two 'hits' in sporadic breast tumorigenesis. We
observed phenotypic similarities between BRCA1 methylated
and familial BRCA1 tumours, based on BRCA1 deletion, TP53
mutations, ER status, young age at diagnosis and tumour grade.
Introduction
Germline mutations in one allele of the BRCA1 or BRCA2
genes significantly increase the risk of developing early-onset
breast cancer [1]. Tumour cells from predisposed individuals
have consistently lost the wild-type BRCA allele [2,3]. The
most prominent feature of BRCA deficient cells is the inability
AI = allelic imbalance; CI = confidence interval; ER = estrogen receptor; FISH = fluorescence in situ hybridisation; OR = odds ratio; PR = proges-
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to repair DNA cross-links and DNA double-strand breaks by
error-free homologous recombination, which probably under-
lies genomic instability and cancer predisposition [4]. Survival
of BRCA deficient cells is generally thought to be dependent
upon dysfunctional checkpoint mechanisms, in which case
tumorigenic potential could be acquired through additional
genomic rearrangements and gene mutations. Indeed, familial
BRCA1 tumours are associated with mutations in the TP53
checkpoint gene, supporting the notion that genomic instabil-
ity is an important driving force in early-onset familial BRCA1
tumorigenesis [5].
Although inherited cancer syndromes are rare, the genes
accounting for them are generally believed to play an important
role in sporadic cancer. It was anticipated, therefore, that
somatic BRCA mutations would be found to contribute to spo-
radic breast carcinogenesis. Surprisingly, somatic BRCA
gene mutations have not been found in sporadic breast
tumours [6,7]. On the other hand, allelic imbalance (AI) at the
BRCA loci, an indicator for loss of heterozygosity, is know to
be a fairly common event in breast cancer [8]. The implications
of AI at the BRCA loci are unknown since Knudson's hypoth-
esis predicts an additional inactivating event on top of AI to be
required for tumorigenesis to occur [9]. For these reasons, the
involvement of the BRCA genes in sporadic breast tumours
has been questioned. An alternative mechanism for BRCA1
inactivation has been suggested to be gene silencing by epi-
genetic mechanisms. Hypermethylation of CpG-island pro-
moters is known to be strongly associated with gene silencing.
Once established, methylation is passed on to daughter cells
during DNA replication by the activity of DNA methyltrans-
ferases, thereby conserving the overall pattern of methylated
CpG-islands [10]. The methylation patterns of virtually all
types of cancer, including breast carcinoma, have been found
to differ extensively from that of the corresponding normal tis-
sue. These alterations are cancer-type specific and include
global genomic hypomethylation as well as non-random hyper-
methylation of normally unmethylated CpG-island promoters
[11,12]. These observations, and others, indicate that epige-
netic modifications could be important in cancer etiology [13].
Several studies have reported hypermethylation of the BRCA1
promoter in sporadic breast and ovarian tumours. Further-
more, BRCA1 methylation has only been found in breast and
ovarian tumours and has been associated with AI at the
BRCA1 locus and reduced BRCA1 gene expression [12,14].
BRCA2  promoter hypermethylation has not been found in
breast tumours, although it has been reported in ovarian
tumours [15,16].
Familial BRCA1  and BRCA2  tumours are associated with
young age of onset and are phenotypically distinct from each
other as well as from sporadic breast tumours [1,17-19]. Con-
ventional histopathological and molecular analyses have dem-
onstrated familial BRCA1  tumours to have a basal-like
phenotype and to be significantly associated with certain fea-
tures, such as AI at the BRCA1 locus, a negative estrogen
receptor (ER) and progesterone receptor (PR) status, a med-
ullary tumour histological type, TP53 mutations and, depend-
ing on the mutation involved, a high tumour grade
[3,5,18,20,21]. Interestingly, gene expression profiling has
revealed similarities between BRCA1 methylated and familial
BRCA1 tumours [17,22]. Similarly, a comparative genomic
hybridisation study has reported a specific pattern of genetic
alterations to be predictive of familial BRCA1 tumours and
BRCA1 methylated tumours [23]. This lends support to the
idea that epigenetic silencing of the BRCA1 gene might chan-
nel tumour progression, akin to an underlying BRCA1 germ-
line mutation resulting in a BRCA-like phenotype. However, a
recent report showing high levels of BRCA1 expression and a
low frequency of BRCA1 promoter methylation in basal-like
sporadic tumours suggests that this might be more complex
[24].
In the present study, we examined the frequency of BRCA1α
promoter hypermethylation in 143 unselected primary spo-
radic breast tumours. All tumours were analysed for AI at the
BRCA1 and BRCA2 loci, TP53 mutations, hormonal receptor
status and age at diagnosis. Copy number alterations at the
BRCA1 locus were further examined by fluorescence in situ
hybridisation (FISH) in the BRCA1 methylated tumours which
were also analysed for BRCA1 protein expression, histological
type and tumour grade. The purpose of the study was to exam-
ine whether the BRCA1 gene could be implicated in sporadic
breast tumorigenesis through epigenetic modifications.
Materials and methods
Study group
The study group consisted of 143 female breast cancer
patients that carried neither the Icelandic BRCA1 5193G→A
nor the BRCA2 999del5 germline mutations [25,26]. DNA
samples from these patients were obtained from the Biological
Specimen Bank of the Icelandic Cancer Society. Tumour DNA
(obtained from fresh/frozen primary breast cancer tissue) and
normal DNA (obtained from blood or from fresh/frozen breast
tissue adjacent to the breast cancer tissue) were available
from each of the patients. Data on tumour grade (Nottingham
tumour grade), histological type, ER and PR status, flow-cyto-
metric DNA index and aneuploidy of the tumours were
obtained from the Department of Pathology, Landspitali Uni-
versity Hospital (Reykjavik, Iceland). This work was carried out
according to permits from the Icelandic Data Protection Com-
mission (2004040264; 200403147) and Bioethics Commit-
tee (99041V2S1; 99111V1S1).
Methylation specific PCR
DNA methylation of the BRCA1  promoter region was
assessed by methylation specific PCR of sodium bisulphite
treated DNA [27]. Tumour DNA and controls (1 µg) were
treated with sodium bisulphite and purified using the WizardAvailable online http://breast-cancer-research.com/content/8/4/R38
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DNA Clean-Up System (catalogue no. A7280, Promega, Mad-
ison, WI) following the manufacturer's recommendations.
Modified DNA was amplified with published PCR primers that
distinguish unmethylated and methylated DNA. Primer
sequences for unmethylated and methylated DNA were as fol-
lows: unmethylated forward, ggt taa ttt aga gtt ttg aga gat g;
unmethylated reverse, t caa caa act cac acc aca caa tca; meth-
ylated forward, ggt taa ttt aga gtt tcg aga gac g; and methyl-
ated reverse, tca acg aac tca cgc cgc gca atc g [28]. The
primers amplified a 182 base-pair (bp) product corresponding
to nucleotides -150 to +32 relative to the main transcription
start site of BRCA1. DNA extracted from blood was used as a
negative control for methylated BRCA1 alleles. DNA extracted
from blood and methylated in vitro was used as a positive con-
trol. The PCR solution (15 µl) contained 1 µl of modified DNA
in 1X Thermo-Start PCR Master Mix (ABgene, Epsom, UK)
and 5 pmol of each primer. The PCR was carried out in a ther-
mocycler with the following conditions: one cycle of 95°C for
15 minutes followed by 35 cycles of 94°C for 30s, 65°C for
30s and 72°C for 60s, ending with one cycle of 72°C for 5
minutes. Then, 6 µl of the PCR product were mixed with 6 µl
of 1X loading buffer (98% formamide, 0.1% xylene cyanol,
0.1% bromophenol blue and 10 mM EDTA) and electropho-
rised on 7.5% polyacrylamide gels.
Allelic imbalance by microsatellite analysis
AI at polymorphic microsatellite markers was analysed by laser
quantification of PCR products. We analysed two intragenic
BRCA1 markers (D17S855 and D17S1323), located within
introns 12 and 20, respectively, and one marker centromeric
to the BRCA1 gene (D17S846) located in region 17q12. Two
BRCA2 markers were analysed, located in region 13q12, cen-
tromeric (D13S260) and telomeric (D13S171) to the gene.
The marker primers were of published sequences available
from The GDB Human Genome Data Base [29]. The primers
were purchased HPLC purified from Eurogentec (Seraing,
Belgium) with the forward primers Cy5 indocarbocyanin
labelled.
The PCR solution (15 µl) contained 50 ng of DNA, 5 pmol of
each primer, 0.2 mM Ultrapure dNTPs (Amersham Pharmacia,
Little Chalfont, Buckinghamshire, UK) and 0.36U Dynazyme
enzyme mix (Finnzymes, Espoo, Finland) with supplied 1X
reaction buffer. A Hot Start was performed by heating the PCR
solution in a thermocycler at 94°C for 2 minutes and cooling
to 85°C before the enzyme was added to the solution. This
was followed by 30 cycles at 94°C for 30s, 64°C to 69°C
(annealing temperature varied depending on which primers
were used) for 30s and 72°C for 60s, ending with 1 cycle of
72°C for 5 minutes.
The PCR products were mixed in a stop solution (100%
deionized formamide and Dextran Blue 2000 (5 mg/ml); Amer-
sham Pharmacia) in ratios varying from 0.13 to 1, denatured at
95°C for 5 minutes and resolved on a 3 mm thick High Reso-
lution Reprogel (Amersham Pharmacia) using an automated
laser fluorescent sequencer (ALF Express DNA Sequencer,
Amersham Pharmacia). Aliquots of 3 to 5 µl of each sample
were loaded onto the gel. The following running parameters
were used: 1,500 V, 60 mA, 25 W, 55°C. The sample interval
was 2s, the running time 300 minutes and the running buffer
1X TBE (Tris-BoricAcid-EDTA). ALFwin Fragment analyser
1.0 software (Amersham Parmacia) was used to compare the
relative quantity of the PCR products. AI was defined if the rel-
ative difference of peaks representing alleles in the tumour and
the corresponding normal DNA reactions was more than 25%.
Fluorescence in situ hybridization
FISH analysis was performed on paraffin embedded and for-
malin fixed breast tumour tissue sections (sliced in 4 µm sec-
tions) using DNA probes for the BRCA1  region and the
centromere region of chromosome 17, simultaneously. The
probe for the BRCA1 region (PAC103014; the Human BAC
Clone Library, Sanger Centre, Hinxton, Cambridge, UK) which
spans the entire BRCA1 gene was labelled with SpectrumO-
range-dUTP (Vysis, Des Plaines, IL, USA) by nick-translation.
Hybridisation efficiency of the BRCA1 probe has previously
been tested in non-malignant breast samples [30]. The probe
for the centromere region of chromosome 17 (clone D17Z1 in
pUC 19: American Type Culture Collection, USA), was used
as a copy number reference for BRCA1 and labelled with
green fluoroscein-11-dUTP (Amersham Pharmacia) by nick-
translation.
Figure 1
Methylation-specific PCR analysis of the BRCA1 promoter region Methylation-specific PCR analysis of the BRCA1 promoter region. Positive (+) and negative (-) controls are seen on the far right. Each lane contains 
products generated from separate PCR reactions using primers specific for (a) non-methylated and (b) methylated BRCA1 alleles. The tumour sam-
ple in lane 1 (L1) shows the presence of a band in both PCR reactions, indicating methylation of the BRCA1 promoter region.Breast Cancer Research    Vol 8 No 4    Birgisdottir et al.
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Tissue sections were deparaffinized, placed in 0.01 M citric
acid solution (pH 6) and heated for 2 × 10 minutes in a micro-
wave oven at maximum power. After cooling, tissue sections
were incubated with pepsin at 37°C for 20 minutes followed
by dehydration. Probes were diluted in t-DenHyb-2 hybridisa-
tion buffer (InSitus Biotechnologies, Albuquerque, NM, USA)
as described by the manufacturer. Tissue section chromo-
somes and probes were simultaneously denatured at 95°C for
10 minutes. This was followed by overnight hybridisation at
37°C in a humid chamber and washing of tissue sections for
3 × 5 min in 0.1X SSC (Saline-Sodium-Citrate) at 60°C and
mounting with 4'-6-Diamidino-2-phenylindole (DAPI) counter-
staining. Fluorescence signals were scored in each sample by
counting the number of single-copy gene and centromeric sig-
nals in at least 100 well-defined nuclei. Deletion of BRCA1
was defined if the copy number ratio was 0.8 or less, which
has previously been used to detect deletion [30]. Deletion of
chromosome 17 was defined if both BRCA1 and centromere
mean copy numbers were 1.5 or less.
Immunohistochemistry
BRCA1 protein expression analysis was performed on forma-
lin fixed and paraffin embedded malignant breast tissue and
adjacent normal tissue (sliced in 4 µm sections), with BRCA1
MS110 antibody (Oncogene Research Products, San Diego,
CA, USA). Tissue sections were deparaffinized, placed in 0.01
M citric acid solution (pH 6) and heated for 2 × 10 minutes in
a microwave oven at maximum power. The sections were then
incubated in 3% H2O2 in order to block endogenous peroxi-
dase activity. The BRCA1 MS110 antibody (100 µg/ml) was
used in 1:50 dilution in 1X Tris buffer and incubated in a humid
chamber at room temperature overnight. For antibody detec-
tion all slides were incubated with StreptABComplex/HRP
Duet, Mouse/Rabbit Kit (Code No. K0492: Dako, Glostrup,
Denmark) reagents following the manufacturer's recommen-
dations. Counterstaining was performed with haemotoxylin.
Positive staining of normal breast epithelial cells that either co-
existed on the tumour sections and/or normal breast tissue
sections from the same breast was used as a control. The pro-
tein expression levels in tumour sections were measured by
eye in three discontinuous classes, as previously described
[31]. When the immunoreactivity was comparable to that of
the normal breast epithelium or nuclear staining was observed
in >50% of tumour cells, it was classified as level 3, that is,
wild-type expression. When the staining was clearly weaker
than normal surrounding cells or nuclear staining occurred in
20% to 50% of tumour cells, it was classified as level 2, that
is, reduced expression. When there was no staining or nuclear
staining occurred in <20% of tumour cells, it was classified as
level 1, that is, absent/markedly reduced expression.
TP53 mutation analysis
TP53 mutation analysis was carried out by PCR amplification
and constant denaturing gel electrophoresis on exons 5–8.
Mutations were confirmed by direct DNA sequencing in an
Figure 2
Allelic imbalance analysis at the BRCA loci Allelic imbalance analysis at the BRCA loci. The electropherograms represent quantification of PCR products from normal DNA (upper) and tumour 
DNA (lower) from the same individual. A signal reduction is evident in the tumour electropherograms, which suggest allelic imbalance (indicated by 
an arrow) at the (a) BRCA1 locus, using the D17S1323 marker, and (b) BRCA2 locus, using the D13S260 marker.Available online http://breast-cancer-research.com/content/8/4/R38
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ALF Express DNA Sequencer (Amersham Pharmacia) as pre-
viously described [32].
Statistical analysis
Proportions were compared by two-tailed Fisher's exact test
using GraphPad InStat3 (GraphPad Software Inc., San Diego,
CA, USA). Associations with P values of <0.05 were consid-
ered to be significant and P values within the range of 0.05 to
0.10 as an indication of an association.
Results
Methylation of the BRCA1 promoter
Hypermethylation of the BRCA1α promoter was assayed in
143 primary sporadic breast tumours. Methylation was
detected in 9.1% (13/143) of the tumours (Figure 1).
Allelic imbalance at the BRCA1 and BRCA2 loci
AI in the BRCA1 region was assessed in all 143 samples (Fig-
ure 2a,b). The frequencies of informative cases for polymor-
phism at the BRCA1  microsatellite marker regions were
72.7% (D17S846), 89.5% (D17S855) and 40.6%
Table 1
Association between BRCA1 methylation and AI at the BRCA loci and other tumor features
Primary sporadic breast tumours BRCA1 promoter methylation P value
Yes (n = 13) No (n = 130)
AI at the BRCA1 locus
Yes 8 (62%) 41 (35%)
No 5 (38%) 77 (65%) 0.0731
ND/NA 12
AI at the BRCA2 locus
Yes 5 (38%) 37 (30%)
No 8 (62%) 85 (70%) 0.5420
ND/NA 8
TP53 mutations
Mutated TP53 gene 5 (38%) 22 (17%)
Wild type 8 (62%) 106 (83%) 0.1299
ND/NA 2
Estrogen receptor
Negative 7 (54%) 33 (25%)
Positive 6 (46%) 97 (75%) 0.0475
ND/NA
Progesterone receptor
Negative 6 (50%) 57 (44%)
Positive 6 (50%) 72 (56%) 0.7699
ND/NA 1 1
Age at diagnosis
≤ 55 years 9 (69%) 57(44%)
>55 years 4 (31%) 73 (56%) 0.0898
AI, allelic imbalance; ND/NA, not determined/not available.Breast Cancer Research    Vol 8 No 4    Birgisdottir et al.
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(D17S1323). The intragenic markers D17S855 and
D17S1323 showed AI in 35.2% and 43.1% of informative
cases, respectively (Additional file 1). The exogenic marker
D17S846 showed AI in 36.5% of informative cases. AI at the
BRCA1 locus was defined if one or both of the intragenic
markers (D17S855, D17S1323) displayed AI. According to
this definition, 37.4% (49/131) of informative tumours had AI
at the BRCA1 locus. Of these 49 tumours, 24 were informa-
tive for both intragenic markers, of which all but one displayed
AI at both regions (95.8%). Of the cases informative for an
intragenic marker and the exogenic marker D17S846 (n = 33),
87.9% displayed AI at both regions.
An indication was found for an association between BRCA1
methylation and AI at the BRCA1 locus (P = 0.0731, odds
ratio (OR) = 3.0, 95% confidenece interval (CI) = 0.9–9.8;
Table 1). Of the eight BRCA1 methylated tumours that dis-
played AI at the BRCA1 locus, five were informative for an
intragenic marker and the exogenic marker. All these five
tumours displayed AI at both regions.
The frequencies of informative cases for polymorphism at the
BRCA2  microsatellite marker regions D13S260 and
D13S171 were 74.1% and 71.3%, respectively. The
D13S260 marker showed AI in 32.1% of informative cases,
and the D13S171 marker in 35.3% of informative cases (Addi-
tional file 1). AI at the BRCA2 locus was defined if one or both
markers displayed AI. According to this definition, 31.1% (42/
135) of informative tumours had AI at the BRCA2 locus. Of
these 42 tumours, 29 were informative for both markers, of
which all but one displayed AI at both regions (96.6%).
AI at the BRCA1 locus was found to be strongly associated
with AI at the BRCA2 locus (P < 0.0001, OR = 7.0, 95%CI =
3.0–16.4) with 26 of 124 (21.0%) informative tumours having
AI at both loci (Table 1). However, AI at the BRCA2 locus was
not found to be associated with BRCA1 methylation (P =
0.5420, OR = 1.4, 95%CI = 0.3–5.3).
FISH analysis at the BRCA1 locus
BRCA1 gene copy number was determined in the BRCA1
methylated tumours by FISH analysis (Additional file 1). Con-
siderable heterogeneity was evident in the nuclei of these
tumour cells (Figure 3a).
A physical deletion was detected at the BRCA1 locus in six
tumours, including four with deletion of chromosome 17
(Table 2). Of these six tumours, all but one (sample 6 in Table
2) showed AI at the BRCA1 locus.
BRCA1 protein expression
BRCA1 protein expression was estimated in all BRCA1 meth-
ylated tumours by immunostaining. Nine of the methylated
tumours were estimated to have class 1 BRCA1 protein
expression, indicating absent or markedly reduced BRCA1
expression (Figure 3b,c; Table 2). Of these nine tumours, all
but two had AI at the BRCA1 locus (Table 2). Four tumours
were estimated to have class 2 or 3 BRCA1 protein expres-
sion (Table 2). Of these four tumours, AI at the BRCA1 locus
was detected in one case (Table 2).
TP53 mutation analysis
Of the 143 primary sporadic breast tumours in this study, 141
were available for TP53 mutation analysis. Mutation was found
in 19.1% (27/141) of the tumours. Although not statistically
significant, we found the frequency of TP53 mutations to be
much higher within the subset of BRCA1 methylated tumours
compared with the non-methylated BRCA1 tumours or 38.5%
(5/13) compared to 17.2% (22/128), respectively (P =
0.1299, OR = 3.0, 95%CI = 0.9–10.1; Table 1). However,
TP53 mutations were only found in those BRCA1 methylated
tumours that exhibited absent or markedly reduced BRCA1
expression, in which case the TP53  mutation frequency
becomes 55.5% (5 of 9) and the association statistically sig-
nificant (P = 0.01317, OR = 6.13, 95%CI = 1.21–33.51;
Table 2). All the five tumours with BRCA1 methylation and
Figure 3
BRCA1 gene copy number and protein expression analysis on breast  tumor sections BRCA1 gene copy number and protein expression analysis on breast 
tumor sections. (a) Tumor cells in a BRCA1 methylated sample are 
seen to have reduced BRCA1 gene copy numbers (red signal) com-
pared with centromere 17 (green signal) by FISH. Considerable hetero-
geneity in BRCA1 gene copy numbers was evident in all tumours 
analysed. (b) A BRCA1 methylated tumour section showing wild-type 
BRCA1 protein expression by immunostaining in normal breast ducts 
and (c) absent/markedly reduced BRCA1 protein expression in tumour 
cells. Bars = 7 µm.Available online http://breast-cancer-research.com/content/8/4/R38
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TP53 mutation were found to have AI at the BRCA1 locus
(Table 2). Furthermore, all five tumours showed absent or
markedly reduced BRCA1 protein expression (Table 2).
Hormonal receptor status and age at diagnosis
Association was found between a negative ER status and
BRCA1 methylation (P = 0.0475, OR = 3.4, 95%CI = 1.1–
10.9; Table 1). No associations were found between BRCA1
methylation and a negative/positive PR status.
An indication for an association between young age (= 55) at
diagnosis and BRCA1 methylation was found (P = 0.0898,
OR = 2.9, 95%CI = 0.8–13.4).
Tumour grade and histological type
Of all the 13 BRCA1  methylated tumours, seven were of
grade 3, five of grade 2 and one of grade 1. All BRCA1 meth-
ylated tumours were of infiltrating ductal type except for one
that was of a lobular type.
Discussion
We report here that hypermethylation of the BRCA1 gene pro-
moter is found in a considerable proportion of primary spo-
radic breast carcinomas, that is, 13 of 143 (9.1%), which is in
the lower end of previously reported frequencies for this alter-
ation in sporadic breast tumours [14,33,34].
Absent or markedly reduced BRCA1 protein expression was
evident in the majority of the BRCA1 methylated tumours (9 of
13), suggesting transcriptional silencing in these tumours by
epigenetic modifications. A trend for AI at the BRCA1 locus
was observed in the subset of BRCA1 methylated tumours (P
= 0.0731). All the BRCA1 methylated tumours that had AI at
the BRCA1 locus and were informative for AI at the exogenic
and an intragenic marker displayed AI at both regions, indicat-
ing a rather large deletion at chromosome 17. This is sup-
ported by the FISH analysis, which revealed deletion of
chromosome 17 in most of the BRCA1 methylated tumours
that had a detectable BRCA1 deletion. Importantly, the FISH
analysis revealed substantial heterogeneity in BRCA1 gene
copy numbers between individual cells in the BRCA1 methyl-
ated tumours, demonstrating that AI as detected by polymor-
phic microsatellite PCR analysis does not infer a simple loss of
one BRCA1 allele but, rather, it appears to reflect complex
genetic rearrangements.
AI at the BRCA1 and BRCA2 loci are know to be relatively
common in breast tumours [8]. The implications of AI at the
BRCA1 and/or BRCA2 loci for sporadic breast tumorigenesis
remain unknown since Knudson's hypothesis predicts that two
'hits' are required for tumorigenesis to occur [9]. Our results
confirm that AI at the BRCA1 and BRCA2 loci are common
events in sporadic breast tumours, present in 37.4% (49/131)
and 31.1% (42/135) of primary sporadic breast tumours,
respectively. A significant association was found between AI
at the BRCA1 and BRCA2 loci (P < 0.0001). Importantly, we
found an indication for AI at the BRCA1 locus to be associ-
ated with BRCA1 methylation (P = 0.0731) whereas AI at the
BRCA2 locus was not found to be associated with BRCA1
methylation (P = 0.5420). This has not been shown previously
and suggests that AI at the BRCA1 locus is specifically asso-
ciated with BRCA1 methylation. Thus, copy number altera-
Table 2
Phenotypic features of the BRCA1 methylated tumors
Tumour number AI at BRCA1 AI at BRCA2 TP53 mutation ER status PR status BRCA1 protein 
expressiona
DNA index Interpretation of FISH
1 + - - + + 1 NA Deletion of the BRCA1 region
2 + - - - - 1 1.68 Deletion of the BRCA1 region
3 + + + - - 1 1.12; 1.99 Chromosome 17 deletion
4 + + + - - 1 1.54 Chromosome 17 deletion
5 +++++ 1 1 . 2 2 ;  2 . 1 8 C h r o m o s o m e  1 7  d e l e t i o n
6 - - - + + 1 NA Chromosome 17 deletion
7 + - + - - 1 3.32 No detectable BRCA1 deletion
8 - - - + + 1 1.11; 1.80 No detectable BRCA1 deletion
9 + + + - - 1 1.00 No detectable BRCA1 deletion
10 - - - + + 2 1.69 No detectable BRCA1 deletion
1 1 ----- 31 . 0 0 N o  d e t e c t a b l e  BRCA1 deletion
12 - - - + + 3 2.09 No detectable BRCA1 deletion
13 + + - - NA 3 NA No detectable BRCA1 deletion
aBRCA1 protein expression in class 1 represents markedly reduced or absent expression; expression levels in class 2 and class 3 represent 
reduced and wild-type expression, respectively. AI, allelic imbalance; ER, estrogen receptor; NA, not available; PR, progesterone receptor.Breast Cancer Research    Vol 8 No 4    Birgisdottir et al.
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tions and epigenetic silencing of the BRCA1 gene in sporadic
breast cancer could serve as Knudson's 'hits', which has pre-
viously been proposed by Esteller and colleagues [35].
Indeed, all but one of the BRCA1 methylated tumours that had
absent/markedly reduced BRCA1 protein expression (8 of 9)
also had a detectable deletion of the BRCA1 gene. Collec-
tively, these results suggest that the BRCA1 gene is impli-
cated in sporadic breast tumorigenesis through epigenetic
silencing and deletion of the BRCA1 gene. Indications that
BRCA1 methylation is important in hereditary breast cancer
have been reported [35].
The failure to detect a BRCA1 deletion in one of the tumours
that exhibited absent or markedly reduced BRCA1 expression
could mean that promoter hypermethylation is present on both
alleles, thereby alleviating any selection pressure for deletion
at the BRCA1 locus. Alternatively, the level of detection in the
FISH analysis could be limited by the small proportion of
tumour cells present in each tumour section analysed. This
might also apply for those tumours in which AI was present
without a detectable deletion by FISH. Conversely, the detec-
tion level of the AI analysis was limited by the fact that none of
the tumours were micro/macrodissected prior to DNA isola-
tion, which also means that unmethylated BRCA1 alelles are
always detected in the tumour samples due to the presence of
normal DNA.
The four BRCA1 methylated tumours that did not exhibit sig-
nificantly reduced BRCA1 expression could possibly be heter-
ogenous with respect to this alteration. None of the four
tumours exhibited BRCA1 deletion by FISH and only one dis-
played AI at the BRCA1 locus. Alternatively, DNA methylation
might not bring about transcriptional silencing in all instances.
Although the etiology of cancer predisposition in individuals
carrying a germline BRCA1 mutation is not clear, increased
genomic instability in BRCA1 deficient cells is undoubtedly of
importance since it is predicted to result in increased probabil-
ity of further genetic alterations and gene mutations, which
might result in functional consequences by which tumorigenic
potential could be acquired. Genomic instability, however, is a
potent inducer of apoptosis where cell survival is dependent
upon dysfunctional checkpoint mechanisms [4]. Indeed, famil-
ial BRCA1 tumours are associated with mutations in the TP53
checkpoint gene, supporting the notion that genomic instabil-
ity is an important driving force in early-onset familial BRCA1
tumorigenesis [5]. Association of BRCA1  methylation with
TP53 mutations has not been shown previously. Our results
show a higher frequency of TP53  mutations among the
BRCA1 methylated tumours compared with the non-methyl-
ated tumours or 38.5% (5 of 13) and 17.2% (22 of 128),
respectively (P = 0.1299, OR = 3.0, 95%CI = 0.9–10.1). This
association was not statistically significant, although the TP53
mutations were found to be entirely limited to those BRCA1
methylated tumours that exhibited absent or markedly reduced
BRCA1 expression, in which case the frequency of TP53
mutations becomes 55.5% (5 of 9) and the association statis-
tically significant (P = 0.01317, OR = 6.13, 95%CI = 1.21–
33.51). Reinforcing this idea is the observation that all the five
BRCA1  methylated tumours with a TP53  mutation had a
detectable BRCA1 copy number reduction and the majority of
these tumours had a relatively high DNA index, suggesting
genomic instability (Table 2).
It has previously been suggested that BRCA1  methylated
tumours might phenocopy familial BRCA1 tumours [36]. In
support of this notion, we observed ER negativity to be signif-
icantly associated with BRCA1 methylation (P = 0.0475), a
well established characteristic of familial BRCA1 tumours pre-
viously reported by Catteau and colleagues [37] and others.
However, Matros and colleagues [24], looking at gene expres-
sion profiles, found a high frequency of BRCA1  promoter
methylation among high-grade ER positive tumours, suggest-
ing a more complex phenotype association. We found an indi-
cation for BRCA1 methylation to be specifically associated
with AI at the BRCA1 locus and an elevated frequency of
TP53 mutations, which has not been reported previously. In
addition, we found a considerable proportion of the BRCA1
methylated tumours (7 of 13) to be of grade 3, with only one
tumour of grade 1, as well as an indication of an association
between BRCA1 methylation and an early age of onset (P =
0.0898) as previously reported by Wei and colleagues [34].
It has been suggested that breast cancers arising in individu-
als carrying a germline mutation in the BRCA genes could
benefit from therapeutic agents that lead to DNA cross-links or
double-strand breaks at replication forks, for example, mitomy-
cin C, cisplatin, diepoxybutane and, more recently, poly(ADP-
ribose) polymerase (PARP) inhibitors [38]. These therapeutic
agents could also be effective for sporadic breast cancers
with abnormalities in the BRCA genes, which is, as shown
here, a considerably larger proportion of all breast cancer
patients than germline BRCA1 or BRCA2 mutation carriers. In
addition, abnormalities in other genes regulating homologous
recombination could also be of relevance. This emphasizes the
importance of developing methods for identifying BRCA-like
cancers, regardless of the underlying alterations [36].
Conclusion
Our results show promoter hypermethylation of the BRCA1
gene in a considerable proportion of all primary sporadic
breast tumours. The majority of the BRCA1  methylated
tumours were found to have absent or markedly reduced
BRCA1 expression, suggesting transcriptional silencing by
epigenetic modifications. In addition, we found an indication
for AI at the BRCA1 locus to be associated with BRCA1
methylation whereas AI at the BRCA2 locus was not associ-
ated with BRCA1 methylation. This indicates that AI at the
BRCA1 locus is specifically associated with BRCA1 methyla-
tion. The genetic alterations at the BRCA1 locus were furtherAvailable online http://breast-cancer-research.com/content/8/4/R38
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examined by FISH, which revealed chromosome 17 deletions
and heterogeneity with respect to chromosomal abnormalities.
These results imply that methylation of the BRCA1 gene is
accompanied by genomic rearrangements at the BRCA1
locus, resulting in loss of genetic material containing non-
methylated  BRCA1  alleles and retention of methylated
BRCA1 alleles. We also found a substantially elevated fre-
quency of TP53 mutations in the subset of BRCA1 methylated
tumours, which has not been reported previously, suggesting
that BRCA1 methylation might lead to alterations in the same
molecular pathways as those known to be commonly altered
in familial BRCA1 tumours. Collectively, these results impli-
cate epigenetic silencing of the BRCA1  gene in sporadic
breast tumorigenesis.
Medullary histological type was not found in the BRCA1 meth-
ylated tumours. However, we observed ER negativity to be sig-
nificantly associated with BRCA1 methylation. We also found
a substantial proportion of the BRCA1 methylated tumours to
be of grade 3 and an indication for an association between
BRCA1 methylation and early age of onset. Thus, our results
indicate phenotypic similarities between BRCA1 methylated
and familial BRCA1 breast tumours.
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